Australian Institute of Health and Welfare (2022) Alcohol, tobacco & other drugs in Australia, AIHW, Australian Government, accessed 08 October 2022.
Australian Institute of Health and Welfare. (2022). Alcohol, tobacco & other drugs in Australia. Retrieved from https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Alcohol, tobacco & other drugs in Australia. Australian Institute of Health and Welfare, 24 August 2022, https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Australian Institute of Health and Welfare. Alcohol, tobacco & other drugs in Australia [Internet]. Canberra: Australian Institute of Health and Welfare, 2022 [cited 2022 Oct. 8]. Available from: https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Australian Institute of Health and Welfare (AIHW) 2022, Alcohol, tobacco & other drugs in Australia, viewed 8 October 2022, https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia
Get citations as an Endnote file:
Harm reduction focuses on identifying and targeting specific risks that arise from alcohol and other drug use. This may include risks to the individual, as well as their family and friends (DoH 2017).
Examples of programs that aim to minimise risky behaviours include:
Take-home naloxone programs enable those people at risk of opioid overdose or adverse reaction, and their friends and family members to access naloxone at community and hospital-based pharmacies, alcohol and drug treatment centres and needle and syringe programs (DoH 2021). Given in a timely manner, naloxone can reverse the effects of opioid overdose.
In 2019, the NDSHS included two new questions about support for drug testing at designated sites (i.e. pill testing) and supervised drug consumption facilities/rooms. These measures were generally well supported, with more people supporting pill testing than drug consumption rooms. Support for both measures was highest among younger people and people who had used drugs in the past 12 months (AIHW 2020).
Australia’s attitude and perceptions towards drugs by region, 2019 report showed that almost 3 in 5 people (57%) supported pill testing at designated sites (AIHW 2022).
Almost 3 in 5 (57%) Australians aged 14 and over supported pill testing and 27% opposed it. Over three-quarters (78%) of people who had recently used drugs supported pill testing, compared with 47% of those who had never used drugs. Over 3 in 5 (61%) people aged 14–39 supported this measure, compared with 53% of people in the age groups from 40 and over. Support for pill testing varied according to demographic factors.
Just under half (47%) of Australians supported supervised drug consumption rooms and 32% opposed it. Nearly two-thirds (65%) of people who had recently used drugs supported this measure, compared with 39% of people who had never used drugs. Half (50%) of people in the age groups between 14 and 39 supported this measure, compared with 44% of people in the age groups from 40 and over. Support also varied by demographic factors.
AIHW (Australian Institute of Health and Welfare) 2020. National Drug Strategy Household Survey 2019. Drug statistics series no. 32. Cat. no. PHE 270. Canberra: AIHW. Viewed 21 July 2020.
AIHW (2022) Australia's attitudes and perceptions towards drugs by region, 2019. Canberra AIHW, accessed 15 July 2022.
DoH (Department of Health) 2017. National Drug Strategy 2017–2026. Canberra: Australian Government. Viewed 12 January 2018.
DoH 2021. About the take home naloxone pilot. Canberra: DoH. Viewed 18 June 2021.
Dolan K, MacDonald M, Silins E & Topp L 2005. Needle and syringe programs: a review of the evidence. Canberra: Australian Government Department of Health and Ageing. Viewed 25 January 2018.
Penington Institute (2018). Saving Lives: Australian naloxone access model. Melbourne: Penington Institute. Viewed 16 April 2020.
Sutherland R, Uporova J, Chandrasena U, Price O, Karlsson A, Gibbs D, Swanton R, Bruno R, Dietze P, Lenton S, Salom C, Daly C, Thomas N, Juckel J, Agramunt S, Wilson Y, Woods E, Moon C, Degenhardt L, Farrell M and Peacock A. 2021. Australian Drug Trends 2021: Key Findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney.
Thomas N, Juckel J, Daly C, Maravilla J, & Salom C R 2021. Trends in self-reported past year non-fatal overdose and responses to overdose: Findings from the Illicit Drug Reporting System. Sydney. National Drug and Alcohol Research Centre, UNSW.
Uniting 2017. Uniting Medically Supervised Injecting Centre: get to know our story. Viewed 25 January 2018.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.